

INT-767

## Chemical Properties


CAS No. : 1000403-03-1

Formula: C<sub>25</sub>H<sub>43</sub>NaO<sub>6</sub>S

Molecular Weight: 494.66

Storage: Keep away from moisture, Store at low temperature  
Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	INT-767 is a potent farnesoid X receptor (FXR)/TGR5 dual agonist that prevents NASH and promotes visceral adipose brown lipogenesis and mitochondrial function for the study of non-alcoholic steatohepatitis.
Targets(IC50)	FXR, Autophagy, GPCR19
In vitro	INT-767 does not inhibit hERG, indicating that this compound should not induce cardiac toxicity because of inhibition of the potassium channel[2].
In vivo	Mice were treated daily with INT-767 (10 and 20 mg/kg) or vehicle alone (40% 2-hydroxypropyl-β-cyclodextrin) via intraperitoneal injection for 2 weeks. The results showed that INT-767 reduced the levels of plasma total cholesterol, high-density lipoprotein cholesterol, and triglycerides in both db/m and db/db mice [2].

## Solubility Information

Solubility	DMSO: 80 mg/mL (161.73 mM), Sonication is recommended. H <sub>2</sub> O: 80 mg/mL (161.73 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (6.67 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	2.0216 mL	10.108 mL	20.2159 mL
5 mM	0.4043 mL	2.0216 mL	4.0432 mL
10 mM	0.2022 mL	1.0108 mL	2.0216 mL
50 mM	0.0404 mL	0.2022 mL	0.4043 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

- Baghdasaryan A, et al. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2<sup>-/-</sup> (Abcb4<sup>-/-</sup>) mouse cholangiopathy model by promoting biliary HCO<sub>3</sub><sup>-</sup> output. *Hepatology*. 2011 Oct;54(4):1303-1312.
- Rizzo G, et al. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. *Mol Pharmacol*. 2010 Oct;78(4):617-630.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286    E\_mail: info@targetmol.com    Address: 34 Washington Street, Wellesley Hills, MA 02481